Industry struggling for business damage recovery caused by NHI policy changes on combined drugs.

Published: 2006-07-28 06:58:00

Updated: 2006-07-28 06:58:00

The recent government reschedule policy for the combined non-prescription drugs gave an enormous business impact to the pharmaceutical industries and markets, bringing out about 165.9 BW of sales plummet for 742 products.

The top products to receive critical business damages thereby included A...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK